Fexinidazole 是具有口服活性的硝基咪唑抗锥虫药物。它显示出对布鲁氏杆菌亚种和菌株的杀锥虫活性，IC50值为 0.7-3.3 μM (0.2-0.9 μg/ml)。它具有用于因感染布鲁氏菌引起的人类昏睡病的潜力。

Fexinidazole is an antiparasitic agent. It has activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.

Promoter-luciferase reporter assay: A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5

59729-37-2

C12H13N3O3S

279.31

非昔硝唑;HOE 239

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years